Kras, Hras or Nras mutations occur at varying frequencies across different tumors in humans for unknown reasons. A new study shows that, in mice, locus-specific regulatory elements determine whether mutations in Hras or Kras will predominate in lung and skin tumors.
This is a preview of subscription content, log in via an institution to check access.
References
Bos, J.L. Cancer Res. 49, 4682–4689 (1989).
To, M.D. et al. Nat. Genet. 40, 1240–1244 (2008).
Kohl, N.E. et al. Nat. Med. 1, 792–797 (1995).
Johnson, B.E. & Heymach, J.V. Clin. Cancer Res. 10, 4254s–4257s (2004).
Mijimolle, N. et al. Cancer Cell 7, 313–324 (2005).
Konstantinopoulos, P.A., Karamouzis, M.V. & Papavassiliou, A.G. Nat. Rev. Drug Discov. 6, 541–555 (2007).
Hancock, J.F. Nat. Rev. Mol. Cell Biol. 4, 373–384 (2003).
Potenza, N. et al. EMBO Rep. 6, 432–437 (2005).
Zhang, Z. et al. Nat. Genet. 29, 25–33 (2001).
Johnson, L. et al. Nature 410, 1111–1116 (2001).
Patek, C.E. et al. Exp. Cell Res. 314, 1105–1114 (2008).
Plowman, S.J. et al. Mol. Cell. Biol. 23, 9245–9250 (2003).
Patek, C.E. et al. BMC Gastroenterol. 8, 24 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Berns, A. Kras and Hras—what is the difference?. Nat Genet 40, 1149–1150 (2008). https://doi.org/10.1038/ng1008-1149
Issue Date:
DOI: https://doi.org/10.1038/ng1008-1149
- Springer Nature America, Inc.
This article is cited by
-
Molecules linked to Ras signaling as therapeutic targets in cardiac pathologies
Biological Research (2021)
-
Tissue-specific tumorigenesis: context matters
Nature Reviews Cancer (2017)